- Open Access
Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio
© Molfenter et al.; licensee BioMed Central. 2015
- Received: 14 November 2014
- Accepted: 11 March 2015
- Published: 28 March 2015
Buprenorphine is under-utilized in treating opioid addiction. Payers and providers both have substantial influence over the adoption and use of this medication to enhance recovery. Their views could provide insights into the barriers and facilitators in buprenorphine adoption.
We conducted individual interviews with 18 Ohio county Alcohol, Drug Addiction, and Mental Health Services (ADAMHS) Boards (payers) and 36 addiction treatment centers (providers) to examine barriers and facilitators to buprenorphine use. Transcripts were reviewed, coded, and qualitatively analyzed. First, we examined reasons that county boards supported buprenorphine use. A second analysis compared county boards and addiction treatment providers on perceived barriers and facilitators to buprenorphine use. The final analysis compared county boards with low and high use of buprenorphine to determine how facilitators and barriers differed between those settings.
County boards (payers) promoted buprenorphine use to improve clinical care, reduce opioid overdose deaths, and prepare providers for participation in integrated models of health care delivery with primary care clinics and hospitals. Providers and payers shared many of the same perceptions of facilitators and barriers to buprenorphine use. Common facilitators identified were knowledge of buprenorphine benefits, funds allocated to purchase buprenorphine, and support from the criminal justice system. Common barriers were negative attitudes toward use of agonist pharmacotherapy, payment environment, and physician prescribing capacity. County boards with low buprenorphine use rates cited negative attitudes toward use of agonist medication as a primary barrier. County boards with high rates of buprenorphine use dedicated funds to purchase buprenorphine in spite of concerns about limited physician prescribing capacity.
This qualitative analysis found that attitudes toward use of medication and medication funding environment play important roles in an organization’s decision to begin buprenorphine use and that physician availability influences an organization’s ability to expand buprenorphine use over time.
Additional education, reimbursement support, and policy changes are needed to support buprenorphine adoption and use, along with a greater understanding of the roles payers, providers, and regulators play in the adoption of targeted practices.
- Payer perspectives
- Opioid addiction
- Qualitative research
- Medication-assisted treatment
Buprenorphine is a pharmacotherapy that acts as a partial μ-opiate-receptor agonist . When combined with naloxone, a full μ-opiate-receptor antagonist that can counter the effects of opioids, there is diminished potential for buprenorphine to be abused . Agonist pharmacotherapy for opioid dependence (i.e., buprenorphine, buprenorphine/naloxone combinations, and methadone) improves retention in addiction treatment and reduces the use of illicit opioids [3,4]. Until 2002, methadone, a full μ-opiate-receptor agonist, was the primary pharmacotherapy for opioid dependence; however, methadone is only available in regulated settings that supply limited take-home medication, and is prone to causing adverse reactions . Within this environment, buprenorphine and buprenorphine/naloxone combinations were projected to play an important role in the treatment of opioid addiction when approved by the Food and Drug Administration (FDA) in 2002 for use by authorized physicians . Adoption, however, has been slow, especially among publicly-funded addiction treatment centers; only 17% percent of specialty treatment centers who accept public funds and provide outpatient, intensive outpatient, or residential addiction services offer buprenorphine treatment .
Payers and regulators, in their oversight role, influence the structure of treatment systems and the practices used in treatment centers. Knudsen and Abraham  found that treatment programs were more likely to have adopted pharmacotherapy for addiction, including but not limited to buprenorphine, if they perceived greater support for medications by the Single State Authority overseeing publicly-funded substance abuse treatment services. Treatment programs in states that provided public insurance coverage for buprenorphine were more likely to provide the medication . The payers’ role is not limited to reimbursement policy; payers also influence regulatory policy, contracting requirements, and provider education . Additionally, payers’ level of buprenorphine support varies, and few payers apply the same policy rules to buprenorphine therapy as to they do to medication therapies common to the treatment of other chronic disease conditions . Despite payers’ instrumental role and mixed support, their perceptions of facilitators and barriers to buprenorphine use have been understudied in the health services literature [8,9,12].
Provider facilitators and barriers
Payers contract with treatment agencies (providers) to provide treatment services, including buprenorphine treatment. Addiction treatment centers using buprenorphine are more likely to be accredited or licensed , participate in managed care arrangements , provide detoxification services [9,13,14], employ physicians [13,15], and offer other medication-oriented treatments [14,16,17]. A lack of reimbursement for buprenorphine , philosophical resistance to medication therapy , and limited availability of buprenorphine prescribers  inhibit use of buprenorphine in specialty treatment settings. Treatment practitioners’ perceptions of facilitators and barriers to buprenorphine use and payer priorities must inform policy if buprenorphine-assisted treatment is going to reduce opioid addiction and overdose deaths.
Study setting: opioid trends in Ohio
Nationwide, non-medical use of opioids is significantly influencing public health . Ohio has the 12th highest drug overdose mortality rate in the United States, and Ohio has implemented many of the same opioid prescription misuse policies tested in other states . In 2011, 66.7 doses of prescription opioids were purchased per Ohio citizen, and 1.2 Ohioans died per day due to unintentional overdose of prescription opioids . The increase in patients seeking treatment for opioid dependence challenges Ohio’s publicly-funded system of specialty addiction treatment providers. Ohio treatment providers report that opioid-dependent patients make up more than a quarter of all clients served, and nearly 80 percent of providers reported increased wait times for assessment services due to increased treatment demand .
Ohio currently (2015) provides outpatient methadone therapy, but is limited to 13 locations. With the small number of methadone locations, methadone’s limited take-home availability, and the prevalence of opioid abuse, buprenorphine treatment is seen as a key strategy for reducing the adverse effects of opioid dependence in Ohio . At present, 22% of Ohio treatment providers use buprenorphine to support recovery and 43% make referrals to physicians authorized to prescribed buprenorphine . This is higher than the national buprenorphine use rate of 17% , but falls considerably short of 100% use.
Publicly funded addiction treatment in Ohio is administered through Alcohol, Drug Addiction, and Mental Health Services (ADAMHS) boards (henceforth referred to as “county boards”) (n = 53) and each board represents one to five counties. ADAMHS boards support specialty addiction treatment services using state and local appropriations combined with the federal Substance Abuse and Prevention Treatment (SAPT) block grant. The Substance Abuse and Mental Health Services Administration (SAMHSA) provides the SAPT funds, which are intended for the uninsured and fund up to 55% of addiction treatment services . Within states, counties and other fiscal intermediaries often perform logical and meaningful roles in the distribution of addiction funds. In the United States, 34% of these addiction treatment funds are allocated by county or regional entities.
The county board structure creates many contrasting payer environments in Ohio. Our qualitative study compares perceived facilitators and barriers to buprenorphine adoption among Ohio’s payers (the county boards) and providers, and describes why payers and providers do or do not support the use of buprenorphine to treat opioid dependence.
Setting and recruitment
A community trial studied an intervention to increase use of buprenorphine and other medications for opioid dependence in Ohio. County boards and substance abuse treatment provider interviews were conducted during the pre-implementation phase of this trial . County board participants (N=18) and treatment provider agency participants (N=36) with greater than 100 admissions per year were recruited (September 1, 2012 to October 31, 2012) and completed the individual interviews (November 1, 2012 to February 28, 2013) by telephone. The county boards represented 27 of Ohio’s 88 counties, and these boards support 65 treatment agencies with more than 100 annual admissions. A representative sample of county board participants was selected, stratified on 20% opioid admissions of total admissions (above/below) and 200,000 people covered (above/below). Three county boards that were not participating in the trial were interviewed to reduce selection bias. No other Ohio county boards were approached to participate in this study. All county boards referred two organizations. These organizations represented 55.4% (36/65) of the organizations eligible in those county board areas. Participating counties represented 44.2% (65/315) of all treatment providers in Ohio with more than 100 admissions per year. No organizations refused to participate in the qualitative interviews.
For the county board interviews, the board’s highest-ranking clinical officer or the executive director completed the interview. These individuals tend to be responsible for adopting new clinical practices; they also encounter the facilitators and barriers directly during clinical practice implementation. Two treatment agencies were interviewed in each county board area to capture multiple perspectives. A clinical manager with direct exposure to the facilitators and barriers of the buprenorphine adoption process completed the agency interviews.
Data collection procedures
Three members of the research team conducted interviews. The principal investigator trained two members of the research team and observed their first two county board and provider interviews. The interview guide was pilot tested with two county boards and two providers. The final interview guide addressed knowledge of barriers and facilitators to buprenorphine use for the county boards and providers. The county boards were asked whether or not they support buprenorphine use, and what caused them to support or not support buprenorphine adoption. These were asked as general questions, and no specific issues were solicited. The semi-structured format allowed for standardization across interviews and for the interviewer to probe for additional information when appropriate.
The research team used data from the state’s pharmacy management and addiction treatment database to calculate buprenorphine use rates by county (i.e., individuals with a buprenorphine prescription during 2012 divided by the number of opioid dependent individuals admitted to the public treatment system by county). The study received approval from the institutional review boards at the University of Wisconsin–Madison and the Ohio Department of Health.
The review of the qualitative data followed a summative qualitative content analysis procedure . Interviews were transcribed for review and four members of the research team coded the transcripts. The multi-disciplinary research team (with backgrounds in addictions, operations management, and education) ensured multiple viewpoints and vigorous discussion of the data. The first step in the coding process involved open coding. Transcripts were coded and analyzed using ATLAS.ti . Two team members coded each transcript independently to enhance reliability. An inductive approach for analyzing qualitative data identified codes and concepts within each interview . Codes and concepts were grouped by county board and provider. The researchers sought consensus on code nomenclature and content to ensure more consistent coding. Upon reaching consensus on broad thematic codes and their working definitions, the team revisited the interviews with the preliminary coding scheme. At this stage, to ensure consistency across coders, we examined agreement across a random selection of interviews. Items with discrepant codes were discussed until consensus was reached. No coded comments were discarded throughout the coding process. When coding was complete, queries of specific codes were generated. Summaries were generated for the common themes, with examples of text from each theme. Quotes were chosen to illustrate themes expressed by respondents based on clarity, brevity, variety, and their representation of similar comments from a range of participants.
Participant site characteristics – county boards and provider agencies
Interviewee site characteristics
County (n = 18)
General job description
Funds available for buprenorphine*
SAPT Block Grant
Provider (n = 36)
General job description
Physicians on staff
Full-time staff equivalents (FTEs)
Use of methadone on-site
Refer to other providers
County board reasons for buprenorphine adoption
All county boards interviewed stated support for the use of buprenorphine for opioid treatment, with no boards opposed to use of buprenorphine. County boards reported three reasons for supporting the adoption of buprenorphine: the escalating rates of opioid dependence/opioid crisis, the need for better care, and integration with general health care.
“We identified this huge increase in opioid addiction coming through the door. That is what kicked off our search for what are the best practices out there and that is how we got involved with buprenorphine and medication-assisted treatment.” (Board Quote)
“We’re really looking at buprenorphine to get people retained in treatment until they have the skills to stay sober in the long term, until they have the recovery supports around them.” (Board)
“Now is the time to be smart about everything going into the integration of behavioral health and medical health. It’s like the train is running and it won’t be too long before it starts to move and it seems obvious for medication-assisted therapy to have its body inside one of the train cars.” (Board)
County board and provider barriers and facilitators
Within a receptive environment for buprenorphine adoption and use, boards and providers identified potential barriers and facilitators to buprenorphine.
County board and provider barriers
Barriers among the county boards and providers were aggregated into five thematic areas: a) negative attitudes toward the use of agonist pharmacotherapy, b) lack of awareness/understanding, c) limited physician availability, d) insufficient funds, and e) diversion concerns.
Most of the themes and sub-themes were consistent between the county board and provider respondents, with few noticeable exceptions. Providers were more concerned about addiction treatment providers’ lack of knowledge of buprenorphine, and also about recovery groups’ hostility toward use of medications for addiction treatment. Representative quotes illustrate the barrier themes and sub-themes, with whether the quote came from a board or provider interview noted.
A) Negative attitudes toward use of medication
“We have had a pretty big struggle in our community, philosophically, about some of our providers…that truly believe that medication-assisted treatment is substituting one drug for another.” (Board)
“I got some staff that are questioning why we would give a drug to an addict.” (Provider)
“I think the Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) community has a lot of prejudice against opioid maintenance therapy.” (Provider)
“Those in recovery say if you are taking a pill, then you’re not in recovery.” (Board)
B) Lack of awareness/understanding
“I think our staff would like to have more education beyond just the initial, here is the chemical make-up of buprenorphine, and here is how it works.” (Provider)
“Most physicians use it [buprenorphine] as they do other pharmacological aids in the sense, that it is a pill, rather than wrapping around a holistic approach with patients.” (Board)
C) Limited physician availability
“Doctors do not want to deal with this population.” (Board)
“We went around to identify different physicians that would be willing to be involved as a referral site for us and we got a tremendous amount of negative or uninterested response.” (Provider)
“We are stuck with federal regulation that says you can only have 100 patients per prescriber.” (Provider)
“This isn’t unique to [our] county… I’ve run into this in other counties and even statewide… physicians get involved, and they get to their 30-patient cap or if they’re beyond their first year, and they get to their 100-person cap. And then they don’t know how to discontinue them, and they’re stuck with this immovable object of a caseload until people start to attrite or they discontinue.” (Board)
D) Insufficient funds
“Well again it’s the lack of funding, we really don’t have any money to fund medication-assisted therapy.” (Board)
“We were struggling with funding issues of how it would be paid for so medications could at least be cost neutral.” (Provider)
E) Diversion concerns
“I think that people outside of the clinical community have this understanding now that buprenorphine has a street value; the whole issue with diversion. I think it is what we face the most concerning the medication.” (Provider)
County board and provider facilitators
The facilitators were aggregated into three thematic areas related to a) providers are knowledgeable (about buprenorphine); b) criminal justice involvement; and c) funding. Again, the county boards and providers tended to share the same perceptions of facilitators. Providers expressed a much greater appreciation for having access to physicians who supported buprenorphine use, while county boards perceived the criminal justice system had a stronger influence on addiction treatment practices.
A) Provider knowledge about buprenorphine
“Every single one of our counselors and therapists is well aware and on board with medication as a fundamental component of treating certain addictions.” (Provider)
“I think in terms of the community, those that are involved with the alcohol and treatment system are very knowledgable.” (Provider)
B) Criminal justice involvement
“It is most important to have criminal justice system behind use of buprenorphine. They are just huge in our county.” (Board)
C) Funding available
“Seventy-five per cent of our funding for buprenorphine is through our local levy. We could not provide buprenorphine therapy without these funds.” (Board)
Use of buprenorphine
The last analysis was to discern what themes were present in county boards that had low or high utilization of buprenorphine. The county boards had varying buprenorphine use rates in 2012, with opioid admissions ranging from 4% to 47% with a mean of 20% (SD 12%). Four county boards with buprenorphine use rates for opioid admissions below 10% were compared with four boards that had rates 30% or greater.
“Our providers have considerable resistance to medication-assisted therapy because it does not follow 12-steps traditions.” (Board)
“We have funds dedicated to buprenorphine therapy, but cannot always expend them due to a shortage of physician prescribers.” (Board)
The analysis addresses how the increase of opioid misuse affects the county boards and providers in Ohio. The county boards uniformly expressed concerns about the growing use of prescription and non-prescription opioids and perceived buprenorphine therapy as a viable treatment option. Statewide, the county boards in Ohio prioritize opioid misuse and have policies to address it . The county boards’ motivation to encourage buprenorphine use was based on their fundamental desire for better clinical care for opioid dependent patients.
It is not uncommon for county boards (or other payers) and providers to have conflicting opinions on issues related to payment policy, clinical care, quality metrics, and necessary treatment capacity [32,33]. However, in this qualitative assessment, county boards and providers had similar thoughts on the barriers and facilitators to buprenorphine use. County boards and treatment providers may be aligned on this issue because they influence each other’s perceptions and must collaborate on a response to the opioid crisis and its effect on the addiction treatment system and local communities.
Review of the findings: based on three thematic drivers
Ideology precluding use of medication and lack of knowledge of the benefits of medication were identified by study participants as important issues. Long-standing traditions and firmly held beliefs steeped in 12-step tradition have been found to influence counselor attitudes towards use of buprenorphine and other medication-assisted therapies . Yet, the abstinence-only approach to detoxification and treatment for opioid disorders has not been effective . On the other hand, medication-assisted therapy possesses an evidence base that supports greater treatment retention and reduced use of illicit opioids [4,36]. Hence, those preferring the behavioral approaches over medication-assisted treatment may be placing ideology over the evidence-base.
Participants’ concerns about anti-medication ideology extended to physicians as well as to counselors. They felt that buprenorphine-specific training could help change attitudes in these key clinical roles.
Studies related to physician’s willingness to prescribe buprenorphine tend to be based on special circumstances such as HIV care  or focused on primary care settings [38,39]. Other authors have recommended that more attention be given to physicians working within addiction treatment programs .
Medicaid reimbursement has been associated with greater use of addiction medications [9,25]. In Ohio, Medicaid pays for buprenorphine therapy, but a significant number of patients remain without health insurance to pay for buprenorphine medication and associated ancillary services. This study did confirm the importance of a funding source for buprenorphine therapy and discovered another payment source for these medications: use of county tax levy funds.
The analysis of high and low buprenorphine use rates suggests that county funding is a primary driver of buprenorphine use in Ohio. Accordingly, payers wanting to expand use of buprenorphine should assure that payment is available for the buprenorphine medication, as well as associated physician time, laboratory tests, and counseling. Our analysis, however, suggests that county funding is necessary but not sufficient. The implementation science literature draws a distinction between adoption and implementation of a practice, with adoption being the first time a person or entity applies the practice and implementation representing the frequency of application after adoption .
For adoption of buprenorphine in Ohio, it seems that funding and mindsets are important. The high-use buprenorphine county board areas had funding for buprenorphine; in low-use buprenorphine county boards areas, oppositional ideologies created barriers to buprenorphine implementation. Yet, two of the low-use county boards had county levy dollars available to support use of buprenorphine. Hence, a combination of amenable ideology and funding supports may be needed to create an attractive environment for adoption activities. Buprenorphine-specific training for counselors and physicians can begin to increase knowledge, resulting in counselors who are more likely to find buprenorphine as acceptable and effective for treating opioid dependence [42,43].
Physician capacity issues were consistently raised as an issue in increasing use following adoption. The DATA 2000 cap of 30 patients per physician in year one and 100 thereafter  creates a clear structural barrier for physicians working in addiction treatment settings. This is particularly the case for physicians who have caseloads of patients on long-term buprenorphine therapy occupying their existing slots. New physicians must be recruited once the existing buprenorphine prescribers are treating their allotted number of patients. This can be difficult when programs must recruit physicians who do not have a background in addiction treatment and lends credence to the proposition by Wood, et al.  to provide greater physician education in addiction medicine. All three of the high volume buprenorphine county board areas needed additional physician buprenorphine prescribing capacity, underscoring the importance of this factor in promoting additional buprenorphine use.
There are limitations based on the sample. Potential selection bias may exist in the county board sample because 15 of the 18 county boards that participated in the qualitative interviews agreed to participate in an intervention study on buprenorphine adoption. The sample only represents the public treatment system in Ohio. However, Ohio has been considered to be on the forefront of states seeking to remedy non-medical use of prescription opioids .
Another limitation is that many beliefs and attitudes were attributed to physicians in the analysis. These beliefs and attitudes were based on payers’ and providers’ observation from regular interactions with physicians, yet were not directly provided by practicing physicians. Additional analyses of buprenorphine beliefs and attitudes should include physicians in the sample to determine how their perspectives compare to those of payers and providers.
Lastly, the interviews were conducted with a limited group of key decision makers from the county boards and provider organizations. While we assumed their comments were representative of issues occurring in the environment, a greater set of interviews within the organizations surveyed as well as other organizations could provide additional input for consideration.
Our study was specific to Ohio, but barriers and facilitators are not unique to this state. This research suggests initial adoption of buprenorphine requires funding and favorable mindsets, while expanded use requires adequate physician capacity. Education can increase knowledge and reduce prejudices against medication-assisted treatment, and policy can play a role in funding supports and physician capacity. Ongoing efforts to promote buprenorphine reimbursement and to remove the physician prescribing caps could help expand use. Lastly, continuing to develop a greater understanding of the unique roles of payers, providers, and regulatory bodies will promote adoption and implementation of buprenorphine and other evidence-based practices.
The research and preparation of the manuscript was supported by a grant from the National Institutes on Drug Abuse (R01 DA030431). We would like to thank Nora Jacobsen, a Senior Scientist at the University of Wisconsin, for her review of the manuscript.
- Greenwald MK, Johanson C, Moody DE, Woods JH, Kilbourn MR, Koeppe A, et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology. 2003;28(11):2000–9.View ArticlePubMedGoogle Scholar
- Stoller KB, Bigelow GE, Walsh SL, Strain EC. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology. 2001;154(3):230–42.View ArticlePubMedGoogle Scholar
- Berglund M. A better widget? Three lessons for improving addiction treatment from a meta‐analytical study. Addiction. 2005;100(6):742–50.View ArticlePubMedGoogle Scholar
- Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2.Google Scholar
- Ling W, Wesson DR. Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend. 2003;70(2):S49–57.View ArticlePubMedGoogle Scholar
- Fiellin DA. The first three years of buprenorphine in the United States: experience to date and future directions. J Addict Med. 2007;1(2):62–7.View ArticlePubMedGoogle Scholar
- Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS Report: Trends in the Use of Methadone and Buprenorphine at Substance Abuse Treatment Facilities: 2003 to 2011. 2013: Rockville, MD.Google Scholar
- Knudsen HK, Abraham AJ. Perceptions of the state policy environment and adoption of medications in the treatment of substance use disorders. Psychiatr Serv. 2012;63(1):19–25.View ArticlePubMed CentralPubMedGoogle Scholar
- Ducharme LJ, Abraham AJ. State policy influence on the early diffusion of buprenorphine in community treatment programs. Subst Abuse Treat Prev Policy. 2008;3(1):17.View ArticlePubMed CentralPubMedGoogle Scholar
- Molfenter T, McCarty D, Capoccia V, Gustafson D. Development of a Multilevel Framework to Increase Use of Targeted Evidence-Based Practices in Addiction Treatment Clinics. Public Health Front. 2013;2(1):11–20.View ArticlePubMed CentralPubMedGoogle Scholar
- Heinrich CJ, Cummings GR. Adoption and Diffusion of Evidence‐Based Addiction Medications in Substance Abuse Treatment. Health Serv Res. 2014;49(1):127–52.View ArticlePubMed CentralPubMedGoogle Scholar
- Andrews CM, D’Aunno TA, Pollack HA, Friedmann PD. Adoption of Evidence-Based Clinical Innovations: The Case of Buprenorphine Use by Opioid Treatment Programs. Med Care Res Rev. 2014;71:46–60.View ArticleGoogle Scholar
- Ducharme LJ, Knudsen HK, Roman PM, Johnson JA. Innovation adoption in substance abuse treatment: Exposure, trialability, and the Clinical Trials Network. J Subst Abus Treat. 2007;32(4):321–9.View ArticleGoogle Scholar
- Knudsen HK, Ducharme LJ, Roman PM. Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors. J Subst Abus Treat. 2006;30(4):363–73.View ArticleGoogle Scholar
- Knudsen HK, Abraham AJ, Oser CB. Barriers to the implementation of medication-assisted treatment for substance use disorders: The importance of funding policies and medical infrastructure. Eval Program Plann. 2011;34(4):375–81.View ArticlePubMed CentralPubMedGoogle Scholar
- Fuller BE, Rieckmann T, McCarty D, Smith KW, Levine H. Adoption of naltrexone to treat alcohol dependence. J Subst Abus Treat. 2005;28(3):273–80.View ArticleGoogle Scholar
- Koch AL, Arfken CL, Schuster CR. Characteristics of US substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. Drug Alcohol Depend. 2006;83(3):274–8.View ArticlePubMedGoogle Scholar
- Horgan CM, Reif S, Hodgin D, Garnick DW, Merrick EL. Availability of addiction medications in private health plans. J Subst Abus Treat. 2008;34(2):147–56.View ArticleGoogle Scholar
- Schroeder SA. An agenda to combat substance abuse. Health Aff. 2005;24(4):1005–13.View ArticleGoogle Scholar
- Substance Abuse and Mental Health Services Administration (SAMHSA). Uniform Reporting System (URS) Output Tables. 2013 [cited 2014 September, 24]; Available from: http://www.samhsa.gov/dataoutcomes/urs/.
- Centers for Disease Control (CDC). DATA2010: The Healthy People 2010 Database. Atlanta, GA: National Center for Health Statistics; 2011.Google Scholar
- Ohio Department of Health, O.o.V.S. 2011 Ohio Drug Overdose Data: General Findings. 2011.Google Scholar
- Sherba RT, Massatti RR, Potts L, Adhikari SB, Martt N, Starr S, et al. A Review of Ohio’s Treatment Capacity in Addressing the State’s Opiate Epidemic. J Drug Policy Anal. 2012;5(1):1–11.View ArticleGoogle Scholar
- Nicholls L, Bragaw L, Ruetsch C. Opioid dependence treatment and guidelines. J Manag Care Pharm. 2010;16(1 Suppl B):S14–21.PubMedGoogle Scholar
- Heinrich CJ, Hill CJ. Role of state policies in the adoption of naltrexone for substance abuse treatment. Health Serv Res. 2008;43(3):951–70.View ArticlePubMed CentralPubMedGoogle Scholar
- Molfenter T, Kim J, Quanbeck A, Patel-Porter T, Starr S, McCarty D. Testing use of payers to facilitate evidence-based practice adoption: protocol for a cluster-randomized trial. Implement Sci. 2013;8(1):50.View ArticlePubMed CentralPubMedGoogle Scholar
- Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277–88.View ArticlePubMedGoogle Scholar
- ATLAS.ti, Version 6.1.16. 2011, Scientific Software Development.Google Scholar
- Thomas DR. A general inductive approach for analyzing qualitative evaluation data. Am J Eval. 2006;27(2):237–46.View ArticleGoogle Scholar
- Substance Abuse and Mental Health Services Administration (SAMHSA) (2000) Drug Addiction Treatment Act of 2000. Title XXXV, Section 3502 of the Children’s Health Act of 2000. [cited 2014 November, 14]. Available at: http://buprenorphine.samhsa.gov/data.html
- Massatti R, Beeghly C, Hall O, Kariisa M, Potts L. Increasing heroin overdoses in Ohio: understanding the issue. Columbus, OH: Ohio Department of Mental Health and Addiction Services; 2014.Google Scholar
- Forrest CB, Villagra VV, Pope JE. Managing the metric vs managing the patient: the physician’s view of pay for performance. Am J Manag Care. 2006;12(2):83–5.PubMedGoogle Scholar
- Higashi T, Wenger NS, Adams JL, Fung C, Roland M, McGlynn EA, et al. Relationship between number of medical conditions and quality of care. N Engl J Med. 2007;356(24):2496–504.View ArticlePubMedGoogle Scholar
- Knudsen HK, DuCharme LJ, Roman PM, Link T. Buprenorphine diffusion: The attitudes of substance abuse treatment counselors. J Subst Abus Treat. 2005;29(2):95–106.View ArticleGoogle Scholar
- Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev. 2010;30(2):155–66.View ArticlePubMedGoogle Scholar
- Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang N, Jones K, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949–58.View ArticlePubMedGoogle Scholar
- Cunningham CO, Kunis HV, Roose RJ, Elam RT, Sohler NL. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med. 2007;22(9):1325–9.View ArticlePubMed CentralPubMedGoogle Scholar
- Hutchinson E, Catlin M, Andrilla HA, Baldwin L, Rosenblatt RA. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014;12(2):128–33.View ArticlePubMed CentralPubMedGoogle Scholar
- Walley AY, Alperen JK, Cheng DM, Botticelli M, Castro-Donlan C, Samet JH, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008;23(9):1393–8.View ArticlePubMed CentralPubMedGoogle Scholar
- Knudsen HK, Abraham AJ, Roman PM. Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011;5(1):21.View ArticlePubMed CentralPubMedGoogle Scholar
- Rabin BA, Brownson R, Haire-Joshua D, Kreuter MW, Weaver NL. A glossary for dissemination and implementation research in health. J Public Health Manag Pract. 2008;14(2):117–23.View ArticlePubMedGoogle Scholar
- Rieckmann T, Daley M, Fuller BE, Thomas CP, McCarty D. Client and counselor attitudes toward the use of medications for treatment of opioid dependence. J Subst Abus Treat. 2007;32(2):207–15.View ArticleGoogle Scholar
- Arfken CL, Johanson C, Menza S, Schuster R. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians. J Subst Abus Treat. 2010;39(2):96–104.View ArticleGoogle Scholar
- Wood E, Samet JH, Volkow ND. Physician education in addiction medicine. Jama. 2013;310(16):1673–4.View ArticlePubMedGoogle Scholar
- Kennedy J, Dipzinski A, Roll J, Coyne J, Blodgett E. Medicare prescription drug plan coverage of pharmacotherapies for opioid and alcohol dependence in WA. Drug Alcohol Depend. 2011;114(2):201–6.PubMedGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.